In a step toward advancing Indian Contract Research, Development, and Manufacturing Organization (CRDMO) sector, eleven of the country’s leading CRDMO companies have come together to launch a dedicated industry body called Innovative Pharmaceutical Services Organization (IPSO), bringing together diverse expertise in discovery, development, biomanufacturing, and other specialized areas.
The eleven CRDMO companies include Syngene, Aragen, Anthem Biosciences, Aurigene, Laxai, Piramal Pharma, Neuland, Sai Life Sciences, TCG Lifesciences and O2H Discovery.
This collective initiative aims to advance India’s CRDMO sector and is dedicated to fostering pharmaceutical and healthcare innovation in India, that supports research, policy advocacy and industry collaboration to drive the next wave of biotech and pharma growth.
A new report, Unleashing the Tiger: Indian CRDMO Sector 2025, published by Boston Consulting Group (BCG) and Innovative Pharmaceutical Services Organization (IPSO) at the ongoing BioAsia 2025 event in Hyderabad, states that the Indian CRDMO sector is at an inflection point, with the potential to grow to $22 - $25 billion by 2035.
The report also reveals that India’s CRDMO sector must overcome five key challenges to sustain growth. It needs a 6-7x talent expansion by 2035, faster regulatory approvals and a stronger tier 1 supplier base to reduce import reliance. Limited funding and high capital costs hinder the 4-5x investment needed, while ESG compliance still lags behind Western peers.
Peter Bains, CEO Designate, Syngene International Ltd. said, "The Indian CRDMO sector is positioned for major transformation, with the potential to become a leader in serving the global biopharma and wider life sciences outsourcing market models. Realizing this opportunity will require change and collaboration among all stakeholders in the Indian CRDMO ecosystem. We will also need to work with and collaborate with the Government to foster a more competitive regulatory and financial ecosystem in India to compete with other geographies. We will need to work with India’s academic ecosystem to ensure a strong flow of highly talented scientists, engineers and technology leaders to ensure we are capability competitive. Only by working together, can we unlock new opportunities in drug discovery, process innovation, and advanced manufacturing, that can strengthen India’s position in the global pharmaceutical value chain."
Manni Kantipudi, CEO and Whole time Director, Aragen Life Sciences Ltd., added, "The shift in global pharma outsourcing, the rapid rise of biologics, and India’s expertise in chemistry and process innovation create a once-in-a-generation opportunity. However, to compete at a global level, Indian CRDMOs must not only scale capabilities in new modalities like ADCs, cell & gene therapies, and RNA therapeutics but also work together to build a resilient supply chain and streamline regulatory pathways. IPSO is committed to driving this change by working closely with stakeholders to improve access to capital, accelerate talent development, and champion policy initiatives that make India an even more attractive destination for pharmaceutical R&D and manufacturing. As an industry, we must come together to shape the future of Indian life sciences and secure our place at the forefront of global innovation”
